v3.26.1
Fair value measurement (Tables) - Veraxa Biotech A G [Member]
12 Months Ended
Dec. 31, 2025
Entity Information [Line Items]  
Schedule of liabilities that are measured at fair value on a recurring basis
       
    SARs
(Level 3)
 
SARs liability, January 1, 2024   17,784,920  
Share based compensation     7,248,741  
Fair value adjustment     8,159,132  
SARs liability, December 31, 2024     33,192,793  
Share based compensation     15,795,532  
Fair value adjustment     22,761,218  
SARs liability, December 31, 2025   71,749,543  

 

    Contingent liability
(Level 3)
 
Contingent liability, January 1, 2024   1,625,167  
Fair value adjustment     474,538  
Contingent liability, December 31, 2024     2,099,705  
Fair value adjustment     799,168  
Contingent liability, December 31, 2025   2,898,873  
Schedule of assumptions used in valuing the SARs and contingent liability
               
    December 31,
2025
    December 31,
2024
 
Stock Price   54.60     36.44  
Volatility     -       75 %
Risk free rate of return     -       4.2 %
Expected term (in years)     -       1.00